You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
瑞普生物(300119.SZ):取得獸藥產品批准文號
格隆匯 04-16 18:37

格隆匯4月16日丨瑞普生物(300119.SZ)公佈,全資子公司瑞普(天津)生物藥業有限公司生產的貓用驅蟲藥通過國家比對文號評價審核,近期獲得了由農業農村部核發的獸藥產品批准文號。米爾貝肟吡喹酮片(貓用)是一款廣譜、高效的複方體內驅寄生蟲藥,可同時驅殺寵物貓體內常見的絛蟲、蛔蟲、鈎蟲等多種寄生蟲,具備廣譜驅蟲、安全可靠、便捷易用、長效防護四大核心優勢。該產品依託公司前沿研發平台,嚴格遵循獸藥研發規範,以國際同類一線產品為參比藥物,結合中國寵物寄生蟲流行特徵與臨牀需求,系統性開展處方篩選、適口性優化和生物等效性等研究,成功打磨出療效可靠、安全可控且適配本土寵物貓健康需求的驅蟲產品。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account